Recro Pharma Inc (NASDAQ:REPH) major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $8.88, for a total value of $115,120.32. Following the transaction, the insider now directly owns 734,269 shares in the company, valued at $6,520,308.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Scp Vitalife Partners (Israel) also recently made the following trade(s):
- On Friday, December 28th, Scp Vitalife Partners (Israel) sold 1,980 shares of Recro Pharma stock. The stock was sold at an average price of $9.44, for a total value of $18,691.20.
Recro Pharma Inc (REPH) traded up $0.02 during mid-day trading on Thursday, reaching $8.78. The company’s stock had a trading volume of 139,400 shares, compared to its average volume of 209,567. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50. Recro Pharma Inc has a 52 week low of $5.81 and a 52 week high of $10.59. The stock has a market cap of $167.91, a P/E ratio of -4.08 and a beta of -0.50.
Several research firms recently commented on REPH. Zacks Investment Research raised Recro Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Piper Jaffray Companies reissued a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $11.65.
COPYRIGHT VIOLATION WARNING: This article was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/04/recro-pharma-inc-reph-major-shareholder-sells-115120-32-in-stock.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.